OasisLMS

Upon completion of this activity, participants should be able to:

• Identify key clinical challenges in the management of patients not eligible for simplified hepatitis C virus (HCV) treatment.
• Evaluate evidence-based strategies for managing HCV in patients with liver-related conditions.
• Recognize the unique considerations in treating HCV in immunosuppressed patients, including those receiving immunosuppressive therapy.
• Apply practical approaches to HCV treatment in medically complex patients, balancing virologic cure, comorbidity management, and long-term risk reduction.

This online educational activity has been planned in accordance with the AASLD Financial Disclosure Policy and ACCME Standards for the Integrity and Independence for Accredited Continuing Education by members of the AASLD Transplant Hepatology Board Review Course faculty, the AASLD Maintenance of Certification Committee and the AASLD Governing Board. As an accredited provider, AASLD must collect information from all planners, faculty and others in the planning and control of continuing medical education (CME) activities to disclose all of their financial relationships with ineligible companies within the prior 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, in ineligible companies. Individuals must disclose financial relationships with ineligible companies regardless of their view of the relevance of the relationship to the education. The American Association for the Study of Liver Diseases (AASLD) has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair balanced, independent, and free of commercial bias. Conflicts, if any, are resolved through one or more processes. All relevant conflicts pertaining to this activity have been mitigated. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. This activity will not offer CE Credits.

Ponni V. Perumalswami, MD (AASLD HCV SIG)

İmran Hasanoğlu, MD (ESGVH)

David Goldberg, MD, MSCE

Massimo Puoti, MD

PRIVACY POLICY: https://www.aasld.org/terms-use-and-privacy-policy